Cargando…

30例不同类型胸部受累Castleman病临床分析

OBJECTIVE: To improve the clinical understanding of Castleman disease (CD) with different types of thoracic involvement, including their clinical features, radiological and pathological findings, diagnosis and current treatment strategies. METHODS: Retrospective analysis of 30 patients diagnosed wit...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357939/
https://www.ncbi.nlm.nih.gov/pubmed/32135633
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.012
_version_ 1783558764111069184
collection PubMed
description OBJECTIVE: To improve the clinical understanding of Castleman disease (CD) with different types of thoracic involvement, including their clinical features, radiological and pathological findings, diagnosis and current treatment strategies. METHODS: Retrospective analysis of 30 patients diagnosed with CD with thoracic involvement and hospitalized between June 2009 and May 2019 in The First Affiliated Hospital of Guangzhou Medical University was performed. Patients were divided into three groups for subsequent analysis based on the clinical data: CD with bronchiolitis obliterans (BO), unicentric Castleman disease (UCD) without BO, and multicentric Castleman disease (MCD) without BO. RESULTS: Among the 30 patients, there were 5 (16.7%) patients diagnosed with BO, 18 (60.0%) patients had UCD without BO and 7 (23.3%) patients had MCD without BO. The average age of MCD without BO patients was significantly older than that of BO and UCD without BO patients [(49.29±5.39) ys vs (27.20±3.76) ys and (37.17±2.87) ys; P=0.005 and 0.034, respectively)]. Pulmonary symptoms were commonly seen in BO group (100%) and MCD without BO group (71.4%). while no pulmonary symptoms were seen in UCD without BO group. Key abnormal laboratory findings were erythrocyte sedimentation rate (ESR) increase (40%in BO group and 57.1% in MCD without BO group) and hypoxia (60% in BO group and 28.6% in MCD without BO group). Other abnormal laboratory findings seen in MCD without BO group included anemia and IgG increase (both 57.1%). Notably, all patients in BO group had extremely severe mixed ventilation dysfunction in the lung function test. CT scan showed lung parenchyma involvement in BO group (100%), in UCD without BO group (11.1%) featured by solitary pulmonary nodule and in MCD without BO group (57.1%) featured by diffuse lesions in bilateral lungs. The size of lymph nodes was significantly smaller in MCD without BO group comparing to that in BO group and UCD without BO group[short diameter (1.83±0.51) cm vs (4.73±1.63) cm and (3.62±0.26) cm; P=0.006 and 0.011, respectively]. All patients (100%) in the BO group had a pathological type of transparent vascular variant while the same pathological type accounts for 88.9% in UCD without BO patients. The predominantly pathological type (57.1%) was plasma cell variant in the MCD without BO group. Oral ulcers presented in all patients in BO group but were relieved after the mass resection and immunomodulatory therapy, but the pulmonary symptoms were still progressively aggravated. Thoracoscopic mass excision was the main treatment for UCD without BO patients while chemotherapy, immunomodulatory and targeted therapy were commonly used for MCD without BO treatment. CONCLUSION: The age, clinical symptom, laboratory finding, lung function, imaging manifestation, pathology, treatment and prognosis were different among the three groups. This classification could improve clinical understanding of the disease.
format Online
Article
Text
id pubmed-7357939
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73579392020-07-16 30例不同类型胸部受累Castleman病临床分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To improve the clinical understanding of Castleman disease (CD) with different types of thoracic involvement, including their clinical features, radiological and pathological findings, diagnosis and current treatment strategies. METHODS: Retrospective analysis of 30 patients diagnosed with CD with thoracic involvement and hospitalized between June 2009 and May 2019 in The First Affiliated Hospital of Guangzhou Medical University was performed. Patients were divided into three groups for subsequent analysis based on the clinical data: CD with bronchiolitis obliterans (BO), unicentric Castleman disease (UCD) without BO, and multicentric Castleman disease (MCD) without BO. RESULTS: Among the 30 patients, there were 5 (16.7%) patients diagnosed with BO, 18 (60.0%) patients had UCD without BO and 7 (23.3%) patients had MCD without BO. The average age of MCD without BO patients was significantly older than that of BO and UCD without BO patients [(49.29±5.39) ys vs (27.20±3.76) ys and (37.17±2.87) ys; P=0.005 and 0.034, respectively)]. Pulmonary symptoms were commonly seen in BO group (100%) and MCD without BO group (71.4%). while no pulmonary symptoms were seen in UCD without BO group. Key abnormal laboratory findings were erythrocyte sedimentation rate (ESR) increase (40%in BO group and 57.1% in MCD without BO group) and hypoxia (60% in BO group and 28.6% in MCD without BO group). Other abnormal laboratory findings seen in MCD without BO group included anemia and IgG increase (both 57.1%). Notably, all patients in BO group had extremely severe mixed ventilation dysfunction in the lung function test. CT scan showed lung parenchyma involvement in BO group (100%), in UCD without BO group (11.1%) featured by solitary pulmonary nodule and in MCD without BO group (57.1%) featured by diffuse lesions in bilateral lungs. The size of lymph nodes was significantly smaller in MCD without BO group comparing to that in BO group and UCD without BO group[short diameter (1.83±0.51) cm vs (4.73±1.63) cm and (3.62±0.26) cm; P=0.006 and 0.011, respectively]. All patients (100%) in the BO group had a pathological type of transparent vascular variant while the same pathological type accounts for 88.9% in UCD without BO patients. The predominantly pathological type (57.1%) was plasma cell variant in the MCD without BO group. Oral ulcers presented in all patients in BO group but were relieved after the mass resection and immunomodulatory therapy, but the pulmonary symptoms were still progressively aggravated. Thoracoscopic mass excision was the main treatment for UCD without BO patients while chemotherapy, immunomodulatory and targeted therapy were commonly used for MCD without BO treatment. CONCLUSION: The age, clinical symptom, laboratory finding, lung function, imaging manifestation, pathology, treatment and prognosis were different among the three groups. This classification could improve clinical understanding of the disease. Editorial office of Chinese Journal of Hematology 2020-02 /pmc/articles/PMC7357939/ /pubmed/32135633 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.012 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
30例不同类型胸部受累Castleman病临床分析
title 30例不同类型胸部受累Castleman病临床分析
title_full 30例不同类型胸部受累Castleman病临床分析
title_fullStr 30例不同类型胸部受累Castleman病临床分析
title_full_unstemmed 30例不同类型胸部受累Castleman病临床分析
title_short 30例不同类型胸部受累Castleman病临床分析
title_sort 30例不同类型胸部受累castleman病临床分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357939/
https://www.ncbi.nlm.nih.gov/pubmed/32135633
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.02.012
work_keys_str_mv AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī
AT 30lìbùtónglèixíngxiōngbùshòulèicastlemanbìnglínchuángfēnxī